DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY WITH EPIRUBICIN, PACLITAXEL AND CMF VERSUS EPIRUBICIN, CMF AND WEEKLY DOCETAXEL OR PACLITAXEL FOLLOWED BY TRASTUZUMAB FOR ONE YEAR IN PATIENTS WITH EARLY BREAST CANCER

被引：0
|
作者：
Fountzilas, G. [1 ]
Gogas, H. [1 ]
Pavlidis, N. [1 ]
Eleftheraki, A. [1 ]
Skarlos, D. [1 ]
Koutras, A. [1 ]
Timotheadou, E. [1 ]
Papandreou, C. [1 ]
Pectasides, D. [1 ]
Dimopoulos, M. [1 ]
机构：
[1] Hellen Cooperat Oncol Grp HeCOG, Data Off, Athens, Greece
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [31] EPIRUBICIN (E) FOLLOWED BY CYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL (CMF) VERSUS PACLITAXEL (T) FOLLOWED BY EPIRUBICIN AND VINORELBINE (EV) IN PATIENTS WITH HIGH-RISK OPERABLE BREAST CANCER
    Guglielmini, Pamela
    Sismondi, Piero
    Farris, Antonio
    Amadori, Dino
    Agostara, Biagio
    Gambi, Angelo
    Catalano, Giuseppina
    Faedi, Marina
    Rubagotti, Alessandra
    Boccardo, Francesco
    ANNALS OF ONCOLOGY, 2009, 20
  • [32] Neoadjuvant chemotherapy with a dose-dense and sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer.: A phase II and pharmacogenomic study.
    Sánchez-Rovira, P
    Sánchez, A
    Ribelles, A
    Dueñas, B
    Cidraque, M
    Dueñas, R
    Jaén, A
    Martinez, E
    Medina, B
    Carrasco, E
    Lozano, A
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S108 - S109
  • [33] Dose-dense and sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab as neoadjuvant chemotherapy in stage II and III breast cancer.: A phase II and pharmacogenomic study.
    Sanchez-Rovira, P
    Duenas, B
    Cidraque, M
    Duenas, R
    Jaen, A
    Sanchez, A
    Martinez, E
    Medina, B
    Carrasco, E
    Lozano, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 29S - 29S
  • [34] Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
    Li, Qing
    Wang, Jiani
    Mu, Yuxin
    Zhang, Tongtong
    Han, Ying
    Wang, Jiayu
    Li, Qiao
    Luo, Yang
    Ma, Fei
    Fan, Ying
    Zhang, Pin
    Xu, Binghe
    CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (04) : 485 - +
  • [35] Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer
    Boccardo, F.
    Rubagotti, A.
    Guglielmini, P.
    Sismondi, P.
    Farris, A.
    Amadori, D.
    Agostara, B.
    Gambi, A.
    Catalano, G.
    Faedi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
    Qing Li
    Jiani Wang
    Yuxin Mu
    Tongtong Zhang
    Ying Han
    Jiayu Wang
    Qiao Li
    Yang Luo
    Fei Ma
    Ying Fan
    Pin Zhang
    Binghe Xu
    Chinese Journal of Cancer Research, 2020, 32 (04) : 485 - 499
  • [37] Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
    Fountzilas, G.
    Dafni, U.
    Gogas, H.
    Linardou, H.
    Kalofonos, H. P.
    Briasoulis, E.
    Pectasides, D.
    Samantas, E.
    Bafaloukos, D.
    Stathopoulos, G. P.
    Karina, M.
    Papadimitriou, C.
    Skarlos, D.
    Pisanidis, N.
    Papakostas, P.
    Markopoulos, C.
    Tzorakoeleftherakis, E.
    Dimitrakakis, K.
    Makrantonakis, P.
    Xiros, N.
    Polichronis, A.
    Varthalitis, I.
    Karanikiotis, C.
    Dimopoulos, A. M.
    ANNALS OF ONCOLOGY, 2008, 19 (05) : 853 - 860
  • [38] Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients
    Sanna, G.
    Pestrin, M.
    Zafarana, E.
    Biagioni, C.
    Cavaciocchi, D.
    Turner, N.
    Di Leo, A.
    Biganzoli, L.
    BREAST, 2013, 22 (05): : 926 - 932
  • [39] Prolonged dose-dense (DD) epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) in breast cancer (BCA) is feasible.
    Dang, C
    Smith, K
    Lake, D
    Fornier, M
    D'Andrea, G
    Seidman, A
    Sklarin, N
    Troso-Sandoval, T
    Sugarman, S
    Gilewski, T
    Robson, M
    Drullinsky, P
    Moynahan, M
    Van Poznak, GR
    Panageas, K
    Smith, M
    Norton, L
    Hudis, C
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S108 - S108
  • [40] FINAL RESULTS OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE III TRIAL (HE10/00) EXPLORING THE EFFICACY OF POSTOPERATIVE DOSE-DENSE SEQUENTIAL CHEMOTHERAPY WITH EPIRUBICIN, PACLITAXEL AND CMF IN HIGH RISK BREAST CANCER PATIENTS
    Gogas, H.
    Dafni, U.
    Dimopoulos, M. A.
    Koutras, A. K.
    Pisanidis, N.
    Bafaloukos, D.
    Skarlos, D.
    Pavlidis, N.
    Papakostas, P.
    Fountzilas, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 78 - 78
12345